More Mesoblast Limited news
Mesoblast LimitedASX: MSB

Update on Heart Failure Trial and Funding of Operations

Jul 1, 2016 at 1:31 AM EDT · Issued by Mesoblast Limited

Filed with ASX · Jul 1, 2016 at 1:31 AM EDT · 3 pages · English

On 6ix: 6ix.com/news/update-on-heart-failure-trial-and-funding-of-operations

Watch Mesoblast's latest call↗Mesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings Call↗

Mesoblast Limited on 6ix

Story so far

  • Positive Heart Failure Trial Results Presented to AHAMar 30, 2016
  • Phase 3 Heart Failure Trial Size Substantially ReducedFeb 11, 2016
  • FDA Clears Phase 3 Heart Failure TrialFeb 11, 2016

Earlier from Mesoblast

  • Update on Global Heart Failure ProgramJun 13, 2016
  • Suspension from Official QuotationJun 3, 2016
  • Mesoblast Receives $6.2m From Aus Govt For R&DMay 20, 2016
  • Mesoblast Provides Q3 Financial Results and Corporate UpdateMay 9, 2016
  • Mesoblast Cells Show Disease Modifying Effects on Knee OAMar 31, 2016

Later from Mesoblast

  • MSB Back Pain Results Presented, Receive Best Science AwardAug 1, 2016
  • Mesoblast P2 Results Show Dose-Related Improvements In RAAug 8, 2016
  • MSB Strengthens US Patent Portfolio For Rheumatic DiseasesAug 16, 2016
  • Preliminary Final Report (Including Appendix 4E)Aug 24, 2016
  • Mesoblast Phase 2 Diabetic Kidney Disease Results PublishedOct 6, 2016
All Mesoblast news releases↗

Follow Mesoblast into a list and get an email when it puts out news.

Follow Mesoblast
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer